Bellicum Pharmaceuticals (NASDAQ:BLCM) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM – Free Report) in a research note released on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Bellicum Pharmaceuticals Price Performance Shares of BLCM opened at $0.11 on Friday. The stock has a 50-day moving average of $0.17 and a two-hundred day […]

Leave a Reply

Your email address will not be published.

Previous post European Wax Center, Inc. (NASDAQ:EWCZ) Sees Large Decline in Short Interest
Next post Cumberland Pharmaceuticals (NASDAQ:CPIX) Receives New Coverage from Analysts at StockNews.com